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Aurora kinases have emerged as potential targets in
cancer therapy, and several drugs are currently un-
dergoing preclinical and clinical validation. Whether
clinical resistance to these drugs can arise is unclear.
We exploited a hypermutagenic cancer cell line to se-
lectmutations conferring resistance to awell-studied
Aurora inhibitor, ZM447439. All resistant clones con-
tained dominant point mutations in Aurora B. Three
mutations map to residues in the ATP-binding
pocket that are distinct from the ‘‘gatekeeper’’ resi-
due. The mutants retain wild-type catalytic activity
and were resistant to all of the Aurora inhibitors
tested. Our studies predict that drug-resistant Au-
rora B mutants are likely to arise during clinical treat-
ment. Furthermore, because the plasticity of the
ATP-binding pocket renders Aurora B insensitive to
multiple inhibitors, our observations indicate that
the drug-resistant Aurora B mutants should be ex-
ploited as novel drug targets.
INTRODUCTION
The Auroras are serine/threonine kinases required for multiple
aspects of mitosis in eukaryotic cells. Aurora A, the ‘‘polar-
kinase,’’ promotes centrosome maturation and spindle assem-
bly (Barr and Gergely, 2007). Aurora B, the ‘‘equatorial-kinase,’’
is required for Histone H3 phosphorylation, chromosome bio-
rientation, the spindle assembly checkpoint, and cytokinesis
(Ruchaud et al., 2007).
After the discovery that they are often deregulated in cancer,
the Aurora kinases have attracted considerable attention as po-
tential targets for cancer chemotherapy. Several Aurora inhibi-
tors have been described, including dual Aurora A/B inhibitors
such as VX-680 and PHA-680632; selective Aurora B inhibitors
such as Hesperadin, ZM447439, and AZD1152; and a selective
Aurora A inhibitor, MLN8054 (reviewed by Taylor and Peters
[2008]). The emerging picture is that these agents have potent
antiproliferative effects, inducing apoptosis in human tumor
cell lines. Importantly, VX-680, PHA-680632, AZD1152, and
MLN8054 have antitumor activity in rodent xenograft models
(Harrington et al., 2004; Soncini et al., 2006; Manfredi et al.,552 Chemistry & Biology 15, 552–562, June 2008 ª2008 Elsevier Ltd2007; Wilkinson et al., 2007). Phase I and II clinical trails are
underway, but results are not yet in the public domain.
The enthusiasm for targeting cell-cycle kinases in cancer has
been fuelled by the success of BCR-ABL inhibitors such as ima-
tinib in the treatment of chronic myeloid leukemia (Sherbenou
and Druker, 2007). However, a sobering lesson has also
emerged: clinical resistance can arise rapidly due to mutations
in the Abl kinase domain that prevent inhibitor binding (Gorre
et al., 2001; Shah et al., 2002). To circumvent imatinib resistance,
second-generation inhibitors with distinct modes of action are
being used; dasatinib and nilotinib were selected on the basis
that they should inhibit imatinib-resistant BCR-ABL mutants
(Shah et al., 2004; Weisberg et al., 2005). Importantly, these in-
hibitors have been used successfully to treat imatinib-resistant
patients (Kantarjian et al., 2006; Talpaz et al., 2006). However,
sequential treatment can yield subclones with compound muta-
tions, thus rendering patients resistant to multiple inhibitors
(Shah et al., 2007). This finding argues that in order to minimize
resistance to selective kinase inhibitors, multiple agents target-
ing a broad range of mutations will be required, analogous to
the use of cocktails to treat HIV (Sawyers, 2005).
The BCR-ABL experience illustrates how a protein kinase can
be effectively targeted, how resistance can emerge, and how ra-
tional combinatorial strategies can overcome resistance (Daub
et al., 2004; Sherbenou and Druker, 2007). Over 50 mutations
in the Abl kinase domain have been implicated in imatinib resis-
tance (Daub et al., 2004; Weisberg et al., 2007). The fact that
these amino acid substitutions do not impair the kinase’s cata-
lytic activity indicates that Abl is a remarkably plastic enzyme.
However, receptor tyrosine kinases such as Abl only constitute
a fraction of the kinome (Manning et al., 2002). Whether other
classes of protein kinase of therapeutic interest have the same
extensive capacity for drug resistance is unclear. In this respect,
it is important to develop tools to predict the type and the effects
of mutations that might arise during clinical evaluation.
Toward this end, we developed what is to our knowledge
a new assay to isolate cell lines resistant to Aurora inhibitors
and used the ZM447439 inhibitor as our benchmark. Sequencing
Aurora cDNAs identified four individual point mutations that are
sufficient to render Aurora B resistant to ZM447439. Three muta-
tions are in the active site, namely, Y156H, G160E, and G160V,
whereas the fourth, H250Y, is near the activation loop. The mu-
tations in the active site also confer resistance to VX-680,
MLN8054, and Hesperadin, indicating that these agents share
common modes of action. Thus, our observations suggest thatAll rights reserved
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cytotoxic agents targeting serine/threonine kinases. Further-
more, the mutations confer resistance against a broad spectrum
of inhibitors representing different chemical classes, thus reveal-
ing the challenges lying ahead in drug design. We suggest that in
order to tackle drug resistance, the mutants described here
should be considered as de novo drug targets. And, finally, we
demonstrate that the drug-resistant Aurora B mutants are pow-
erful tools to delineate the on- and off-target effects of Aurora
inhibitors, demonstrating an important proof of principle applica-
ble to other protein kinase inhibitors.
RESULTS
An Assay to Identify ZM447439-Resistant Cell Lines:
Identification of Aurora B Mutations
To determine whether human cancer cells can develop resis-
tance to Aurora inhibitors, we treated HCT-116 cells with a cyto-
toxic concentration of ZM447439, a selective Aurora B inhibitor
(Girdler et al., 2006). We chose HCT-116 cells because they
are hypermutagenic due to a mismatch repair defect (Glaab
and Tindall, 1997). We therefore suspected that these cells might
contain larger numbers of initial variants for selection under the
conditions of our assay. In addition, HCT-116 cells express little
or no drug transporters, reducing the possibility of resistance
due to induction of drug pumps (Teraishi et al., 2005). At 1 mM,
ZM447439 is potently cytotoxic in colony formation assays
with 200 cells (Figure 1A). However, when 5 3 106 cells
were continuously exposed for 3 weeks,20 colonies appeared,
from which we generated 7 cell lines, designated R1–R7. In col-
ony formation and proliferation assays, 1 mM ZM447439 had no
effect on these lines, demonstrating that they are indeed drug re-
sistant (Figures 1A and 1B). In control cells, ZM447439 inhibits
cell division and suppresses Histone H3(Ser10) phosphorylation
(Ditchfield et al., 2003). However, cell division and H3(Ser10)
phosphorylation were unaffected by ZM447439 in lines R1 and
R2 (Figures 1C and 1D), indicating that Aurora B is still active
in the drug-resistant lines despite the presence of ZM447439.
After the BCR-ABL experience, we asked whether this might
be due to mutations in Aurora B rendering it resistant to the inhib-
itor. Sequencing Aurora cDNAs from the drug-resistant clones
revealed that all seven lines harbored point mutations in Aurora
B, yielding five amino acid substitutions, namely, Y156H,
G160E, G160V, H250Y, and L308P (Figures 1E and 1F). Three
lines harbored two mutations, namely, H250Y in combination
with either G160V (R3 and R4) or G160E (R6). To determine
whether these mutations were in the same allele of Aurora B,
we subcloned and sequenced individual cDNAs. Each cDNA
contained one mutation or the other, but not both, indicating
that the two mutations are in separate alleles. Note that these
lines were also resistant to other compounds related to
ZM447329, namely, ZM2, ZM3 (Girdler et al., 2006), and
AZD1152 (Wilkinson et al., 2007) (data not shown).
Ectopic Expression of Aurora B Mutants Restores
Histone H3(Ser10) Phosphorylation
To test whether the Aurora B mutations are sufficient to cause
drug resistance, we ectopically expressed the mutants as
Myc-tagged fusions in DLD-1 cells (Figure 2A). Importantly, theChemistry & BiologyMyc-tagged Aurora B proteins localized to mitotic centromeres
(Figure 2B) and were catalytically active (Figure 2C), demonstrat-
ing that they are functional kinases. To determine whether the
mutants could restore Aurora B activity upon exposure to
ZM447439, we counted the number of mitotic cells positive for
H3(Ser10) phosphorylation. Although induction of wild-type
Aurora B had no effect, ectopic expression of the Y156H,
G160V, and H250Y mutants clearly restored Aurora B activity
(Figure 2D). The effect of the G160V mutant was particularly pen-
etrant, with >75% of the cells staining positive at 4 mM
ZM447439. The Y156H and H250Y mutants were less effective,
restoring the number of phospho-H3(Ser10)-positive cells in 2
mM ZM447439 to 80% and 45%, respectively. For reasons that
are not clear, Aurora B G160E expressed poorly and is therefore
not characterized further in a cellular context; we do, however,
demonstrate that this mutant is drug resistant in vitro (see be-
low). In addition, L308P did not appear to confer resistance
and is therefore not discussed further.
Drug-Resistant Mutants Rescue Aurora B’s
Cell-Cycle Functions
ZM447439 prevents chromosome alignment, compromises the
spindle checkpoint, and blocks cell division, yielding a potent
cytotoxic effect (Ditchfield et al., 2003). If these phenotypes are
due to Aurora B inhibition, as opposed to an off-target effect,
then they should be reverted by ectopic expression of the
drug-resistant mutants. To test this, we first counted the number
of metaphase configurations in MG132-treated cells. Whereas
ZM447439 reduced the proportion of metaphases from 77%
to 24% in controls (Figure 3A), induction of the G160V mutant
restored chromosome alignment, with 48% of cells reaching
metaphase. Next, we analyzed the spindle checkpoint; whereas
overexpressing wild-type Aurora B had no effect on the ability of
ZM447439 to override a taxol-induced mitotic arrest, inducing
the Y156H and G160V mutants substantially restored spindle-
checkpoint function (Figure 3B). Finally, we analyzed cell divi-
sion; whereas ZM447439 induced cell-division failure and endor-
eduplication in controls, induction of Aurora B G160V restored
a near-normal DNA-content profile (Figure 3C). Quantitating cells
with DNA contents > 4n showed that Aurora B G160V limited
endoreduplication even at higher concentrations of ZM447439
(Figure 3C). Induction of Aurora B Y156H and H250Y also re-
duced endoreduplication in the presence of ZM447439. These
observations therefore provide compelling evidence that the
cell-cycle defects induced by ZM447439 are indeed due to inhi-
bition of Aurora B. To determine whether ZM447439’s cytotoxic-
ity is also due to Aurora B inhibition, we performed colony forma-
tion assays. A total of 2 mM ZM447439 typically reduces the
number of DLD-1 colonies to <10%. Whereas induction of
wild-type Aurora B had no effect, induction of the G160V,
Y156H, and H250Y mutants restored colony numbers to 70%,
50%, and 40% respectively (Figure 3D), indicating that the
Aurora B mutants do indeed confer cytoprotection against
ZM447439.
In Vitro Activity of Aurora B Mutants
To determine the effects of the mutations on Aurora B’s enzy-
matic activity, we purified to homogeneity from bacteria a com-
plex of human Aurora B bound to an activating fragment of15, 552–562, June 2008 ª2008 Elsevier Ltd All rights reserved 553
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Drug-Resistant Aurora B Mutantshuman INCENP (Figure 4A). In vitro kinase assays in which His-
tone H3 was used as a substrate demonstrated that the mutants
were as active as the wild-type complex (Figure 4B). In response
to increasing concentrations of ZM447439, wild-type Aurora B
was inhibited to background levels at ZM447439 concentrations
in the 1–3 mM range (Figure 4C). Whereas the H250Y mutation
only had a mild effect, the Y156H mutation had a pronounced
effect, with an 10-fold reduction of drug efficacy. Strikingly,
the G160V and G160E mutations generated an enzyme com-
pletely insensitive to ZM447439, even at concentrations up to
500 mM (Figure 4D).
Next, we asked if the Aurora B mutants conferred resistance
toward other Aurora inhibitors. The Y156H mutant conferred
very strong resistance to VX-680, with an 50-fold reduction in
drug efficacy (Figure 4E). The effects on Hesperadin were slightly
weaker than those observed with ZM447439 (Figure 4F). As with
ZM447439, the H250Y mutant had a much milder effect on
VX-680 and Hesperadin, whereas both the G160V and G160E
Figure 1. Isolation of ZM447439-Resistant
Cancer Cells
(A) Crystal violet-stained colonies of parental HCT-
116 cells and two drug-resistant lines after 14 days
of exposure to ZM447439.
(B)Proliferationassayshowingcell number after ex-
posure to increasing concentrations of ZM447439,
plotted as a percentage of untreated cells.
(C) DNA-content profiles 24 hr after drug exposure.
(D) Western blots probed to detect phospho-his-
tone H3 (Ser10) and Aurora B 24 hr after exposure
to 0–9 mM ZM447439.
(E) DNA sequences of Aurora B cDNAs in parental
and two drug-resistant lines.
(F) Amino acid substitutions identified in Aurora B
cDNAs.
mutants were strongly resistant to VX-
680 and Hesperadin (Figures 4E and 4F).
Mechanisms of Drug Resistance
To determine how the various mutations
render Aurora B drug resistant, we
soaked crystals of the Xenopus laevis
(Xl) Aurora B:INCENP complex (Sessa
et al., 2005) with ZM447439 and collected
diffraction data to 1.85 A˚ resolution
(Table 1 and see Protein Data Bank
[PDB] code: 2VRX). ZM447439 occupies
the deep ATP-binding cleft at the interface
between the small and the large lobes of
the kinase (Figure 5B), and its binding
does not result in significant conforma-
tional changes relative to the unbound
kinase, which crystallizes in a partially
active state (Sessa et al., 2005).
Y156 (F172 in Xenopus) maps to the
hinge loop connecting the small and large
lobes and is located in the proximity
of prominent aromatic moieties in
ZM447439 (Figure 5C). Altering this resi-
due may weaken van der Waals contacts with the inhibitor.
The most effective resistance-conferring mutations are those
substituting G160, which also maps to the hinge loop, with bulk-
ier residues (Figures 2–4). The structural basis for this is immedi-
ately evident from the structure: the morpholino-propoxy moiety
of ZM447439 extends over the hinge loop (Figure 5D), and the
substitution of G160 (G176 in Xenopus) is expected to create di-
rect steric hindrance (Figure 5E), without interfering with ATP
binding (Figure 5F). Y156 and G160 are also implicated in the
binding of VX-680 and Hesperadin (Figure 4). Although they rep-
resent different chemical classes, these inhibitors have chemical
groups that are equivalent to the morpholino-propoxy moiety of
ZM447439 and that interact with the same region of Aurora B
(Sessa et al., 2005; Cheetham et al., 2007). Thus, the similar
modes of binding explain why all three inhibitors are affected
by the G160V/E mutations.
The third residue, H250 (equivalent to H266 in Xenopus), is lo-
cated just under the activation loop. Although this mutation may554 Chemistry & Biology 15, 552–562, June 2008 ª2008 Elsevier Ltd All rights reserved
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drug binding in the active site, the H250Y protein demonstrated
only marginal resistance toward the Aurora inhibitors in vitro (Fig-
ure 4). However, when we assayed the kinase activity of the Au-
rora B mutants immunoprecipitated from cells, Aurora B H250Y
appeared to be hyperactive; even in the uninduced sample, the
small amounts of protein due to leaky expression resulted in sub-
stantial activity (Figure 2C). Thus, whereas the Y156H and G160V
mutants appear to be genuinely drug resistant, the H250Y mu-
tant may confer cellular resistance by hyperactivating the cata-
lytic activity of the kinase.
Aurora B Active Site Mutants Confer Resistance
to Multiple Aurora Inhibitors
Having established that the Y156H and G160V mutants also ren-
der Aurora B resistant to VX-680 and Hesperadin in vitro (Fig-
ure 4), we asked whether these mutants could be used to delin-
eate on- and off-target effects induced by Aurora inhibitors. It
has been suggested that VX-680 is a dual Aurora inhibitor (Har-
rington et al., 2004; Tyler et al., 2007). Thus, the cell-cycle and
cytotoxic effects of VX-680 could be due to inhibition of Aurora
A, Aurora B, or both. Induction of Aurora B Y156H restored a nor-
mal cell-cycle profile in VX-680-treated cells (Figure 6A). This
demonstrates that the cell-division failure caused by VX-680
must be predominantly due to Aurora B inhibition. Furthermore,
induction of the Y156H mutant restored colony formation, con-
firming that the cytotoxic effects of VX-680 are also due predom-
Figure 2. Aurora BMutants Restore Histone
H3(Ser10) Phosphorylation
DLD-1 transgenic lines were induced with tetracy-
cline, then analyzed.
(A) Immunoblot showing induction of Myc-tagged
Aurora B proteins.
(B) Immunofluorescence images showing centro-
meric localization of exogenous Aurora B proteins.
(C) Immunoprecipitation kinase assays showing
that the Aurora B mutants are catalytically active.
(D) Line graphs quantitating the percentage of mi-
totic cells positive for phospho-histone H3 (Ser10)
in the presence of ZM447449.
(E) Kinase assays showing that the G160V and
Y165H mutants are active in the presence of up
to 3 mM ZM447439.
inantly to Aurora B inhibition (Figure 6B).
Thus, our studies provide very strong
evidence that Aurora B is the relevant in
vivo target for the cytotoxic effects of
VX-680, and these findings illustrate the
formidable potential of drug-resistant
mutants in the validation of the mecha-
nisms of drug toxicity.
Based on the in vitro kinase assays
(Figure 4), we anticipated that the
Y156H and G160V/E mutants would ren-
der cells resistant to Hesperadin. Surpris-
ingly, under conditions in which induction
of Aurora B G160V conferred penetrant
resistance to 2 mM ZM447439, each mu-
tant only conferred limited resistance to 50 nM Hesperadin, as
judged by the ability to rescue the drug-induced cell-division fail-
ure (Figure 6C). These observations strongly suggest that, in ad-
dition to Aurora B, Hesperadin may have another cellular target
that is required for cell division.
Finally, we asked whether the mutants conferred resistance to
MLN8054. Although MLN8054 is selective for Aurora A at submi-
cromolar doses, above 2 mM it inhibits Aurora B (Manfredi et al.,
2007). Consistently, 5 mM MLN8054 prevented DLD-1 cells from
dividing, as judged by the loss of cells with 2n DNA contents
(Figure 6D). However, induction of Aurora B Y156H restored
the 2n population, demonstrating the restoration of Aurora B ac-
tivity (Figure 6D). Similarly, the G160V mutant also reverted the
high-dose effects of MLN8054. Thus, the two mutations in the
catalytic cleft, Y156H and G160V, render Aurora B resistant to
four classes of inhibitor, namely, ZM447439, VX680, Hesperadin,
and MLN8054.
Interestingly, although ectopic expression of Aurora B Y156H
in DLD-1 cells reverted the high-dose cell-cycle effects of
MLN8045 (Figure 6D), it did not restore cloning potential (data
not shown). Consistently, MLN8054 was equally efficient at in-
hibiting colony formation in parental HCT116 and R2, the line
that harbors the Y156H mutation (Figure 6E). This suggests,
therefore, that the cytotoxicity of MLN8054 is not mediated via
Aurora B, but rather via another kinase, most likely Aurora A.
However, if selective inhibition of Aurora A is cytotoxic, then
why does VX-680 not kill cells expressing the drug-resistantChemistry & Biology 15, 552–562, June 2008 ª2008 Elsevier Ltd All rights reserved 555
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Drug-Resistant Aurora B MutantsAurora B mutants (Figure 6B)? We suspect that this is because
the extent of Aurora A inhibition at 200 nM VX-680 is not suffi-
cient to cause cell death, whereas at 1 mM, MLN8054 does inhibit
Aurora A enough to suppress viability.
DISCUSSION
A sobering lesson to emerge after implementation of the new-
generation targeted chemotherapeutics is the rapid emergence
of clinical resistance (Daub et al., 2004; Sherbenou and Druker,
2007). Because drug-resistant subclones are likely to exist prior
to treatment (Roche-Lestienne et al., 2002), combination therapy
with multiple agents with differing modes of action will therefore
be required to circumvent resistance (Carter et al., 2005). The ra-
tional design of appropriate combinatorial approaches will how-
ever require an a priori understanding of a drug’s mode of action
and the mechanisms by which resistance may occur. Here, we
show that point mutations that result in single amino acid substi-
Figure 3. Drug-Resistant Mutants Rescue
Aurora B Function
DLD-1 transgenic lines were induced, exposed to
ZM447439, then analyzed.
(A) Immunofluorescence images showing that in-
duction of Aurora B G160V facilitates chromosome
alignment despite the presence of ZM447439.
(B) Bar graph quantitating the mitotic index of
taxol-treated populations showing that Y156H
and G160V restore spindle-checkpoint function
in the presence of ZM447439.
(C) DNA-content histograms after 24 hr drug expo-
sures showing that Aurora B G160V suppresses
endoreduplication. Line graphs quantitate the per-
centage of cells with DNA contents > 4n.
(D) Crystal violet-stained colonies and line graphs
quantitating colony number after 14 days of expo-
sure to ZM447439.
tutions in the Aurora B kinase domain can
render cancer cells resistant to multiple
Aurora kinase inhibitors. As the same mu-
tations render Aurora B resistant to ZM
compounds, VX-680, Hesperadin, and
MLN-8054, our data indicate that these
agents share common modes of action
and would therefore not make suitable
combinations. Therefore, in order to fully
exploit the Aurora kinases as oncology
targets, second-generation inhibitors
with differing modes of action will be re-
quired. Specifically, drugs that inhibit
the Aurora B mutants described here
will be necessary.
A Genetic Screen to Identify
Drug-Resistant Aurora B Alleles
The genetic screen described here
yielded seven HCT-116 subclones resis-
tant to the ZM series of Aurora inhibitors,
all of which harbored Y156H, G160V/E, or H250Y mutations in
Aurora B. The fact that transgenic expression of these alleles in
DLD-1 cells is sufficient to render them resistant to ZM447439
provides compelling evidence that the drug resistance in the
HCT-116 cells is due to these mutations. Thus, the genetic
screen itself demonstrates that cancer cells can acquire resis-
tance to an Aurora kinase inhibitor, at least one that is relatively
selective for Aurora B. If selective Aurora B inhibitors prove to
have antitumor activity in patients when used as monotherapy
agents, these observations therefore demonstrate that the emer-
gence of clinical resistance is mechanistically possible and thus
highly likely.
Although we identified each drug-resistant allele more than
once, whether the screen was saturating remains to be seen; it
may be possible to identify additional ZM447439-resistant
Aurora B mutants. Would similar screens be useful to identify
Aurora alleles resistant to other inhibitors? The fact that all of
the revertants harbored drug-resistant Aurora B alleles provides
compelling evidence that the cytoxicity induced by 1 mM556 Chemistry & Biology 15, 552–562, June 2008 ª2008 Elsevier Ltd All rights reserved
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deed, we suspect that this screen was fruitful because Aurora
B is the only significant target of ZM447439 at this particular con-
centration. If the cytotoxicity was mediated via two or more tar-
gets, survival would require drug-resistant mutations in two or
more genes, the probability of which is much less likely. To
test this, our selection strategy could be adapted to investigate
the efficacy of combination therapy with multiple inhibitors, for
instance by testing whether mutants are selected when multiple
drugs are combined. Experiments in this direction are underway.
Crossresistance Demonstrates Common
Modes of Action
Based on the BCR-ABL paradigm, drug resistance can result from
substitutions of a given residue in the catalytic cleft with a bulkier
one that occludes inhibitor access (Gorre et al., 2001). Conversely,
Figure 4. In Vitro Activity of Aurora B
Mutants
(A) Wild-type human Aurora B45–344:INCENP835–903
and mutants utilized for the kinase assays.
(B) Time course experiment comparing the activity
of the wild-type and mutant kinases, plus quantifi-
cation.
(C) Wild-type and mutant kinases were incubated
with ZM447439 as indicated, and the reaction was
protracted for 15 min. The DMSO solvent control
(3% v/v) is indicated.
(D) ZM447439 concentrations as high as 500 mM
failed to inhibit the G160V and G160E mutants.
(E and F) (E) The same experiment as described in
(C) was carried out with VX-680 as an inhibitor or
(F) with Hesperadin.
resistance can arise from mutations that
change a bulky residue in direct contact
with the inhibitor into a smaller one, thereby
resulting in the loss of essential van der
Waals contacts (Burgess et al., 2005). In
other cases, the mutated residue may not
be in direct contact with the inhibitor but
may change the conformation of the ki-
nase, thus affecting inhibitor binding indi-
rectly. Examining the crystal structure of
Xenopus Aurora B bound to ZM447439 in-
dicates that substituting glycine 160 with
bulkier valine or glutamic acid probably
occludes inhibitorbinding. The Y156H sub-
stitution, also affecting a residue in the cat-
alytic cleft, confers resistance to high drug
concentrations both in vitro and in cells, al-
beit not to the same extent as G160V/E.
Our structural analysis suggests that resis-
tance caused by mutations at this site
might arise due to the loss of productive
van der Waals contacts with the inhibitor,
although we cannot exclude that steric
hindrance also plays a role.
The third amino acid identified, histi-
dine 250, is distal to the inhibitor-binding
site, adjacent to the T loop of Aurora B. H250Y might alter Aurora
B’s conformation, thereby altering inhibitor binding. Alterna-
tively, in light of its proximity to the T loop, this mutation might
enhance the activity of the kinase such that elevated inhibitor
concentrations are required to suppress Aurora B function.
Whereas the in vitro assays indicate that H250Y does not appear
to hyperactivate the recombinant Aurora B:INCENP complex,
the activity associated with H250Y immunoprecipitates is higher
than with the wild-type enzyme. Thus, the activating effect of
H250Y may require some element of Aurora B’s cellular context
that is not recapitulated by the binding to the INCENP IN-box
in vitro.
General Insights into Kinase-Inhibitor Interactions
The rather surprising picture emerging from our studies and from
previous studies on Abl and other tyrosine kinases is that theChemistry & Biology 15, 552–562, June 2008 ª2008 Elsevier Ltd All rights reserved 557
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lines the ATP-binding site. A discouraging consequence of this
fact is that these mutations are likely to affect a wide range of
ATP-competitive inhibitors—even ones from distinct chemical
classes—as most ATP competitors are sensitive to the active
site’s architecture, to which the mutated residues contribute
considerably. Further studies with a wider collection of inhibitors
will be required to analyze this problem in greater detail. How-
ever, we suspect that mutations in residues such as Y156 and
G160 of Aurora B could have more generalized effects than
those caused by mutations in the ‘‘gatekeeper’’ residue. The lat-
ter lies at the periphery of the ATP-binding site and only contrib-
utes to the binding of a subset of extended compounds, such as
imatinib in the case of Abl. Mutations in residues such as Y156
and G160, which literally line the ATP-binding pocket, are likely
to affect the binding of any ATP-competitive inhibitor that targets
Aurora B’s active site. Indeed, a G321E mutation, which is equiv-
alent to the G160E mutation we report, was initially predicted by
an in vitro screen on the Abl kinase, and it was later found to be
present in patients who relapsed after imatinib treatment of
chronic myelogenous leukemia (CML) (Chu et al., 2005). Abl mu-
tations at F317, which is equivalent to Y156 in Aurora B, to L or I
(F317L/I) occur with good frequency during treatment with
imatinib, although not at the same frequency of mutations in
the gatekeeper residue (Melo and Chuah, 2007; Weisberg
et al., 2007).
Table 1. Data Collection and Refinement Statistics
AuroraB60–361:INCENP790–847:
ZM447439
Data Collection
Space group P21
Beamline ID14-3
Unit cell dimensions (A˚) 45.735, 67.004, 116.583
Unit cell angles () 96.93
Resolution (A˚) 30.0–1.85 (1.92–1.85)
Total observations 523,418
Unique reflections 59,143
Data completeness (%) 92.7
Rsymm (%)
a 4.2 (33.3)b
I/sI 19.19 (2.68)b
Refinement
Resolution range (A˚) 30.0–1.85
Rconv
c/Rfree
d 18.81/24.32
Number of atoms in refinement 5,911
Rmsd bond lengths (A˚) 0.008
Rmsd bond angles () 1.160
Mean B factor (A˚2) 26.25
a Rsymm =
PjI  <I>j/P I, where I is the observed intensity of a reflection
and <I> is the average intensity obtained from multiple observations of
symmetry-related reflections.
b Values in parentheses refer to the outer-resolution shell.
c Rconv =
PjjFoj  jFcjj/
P jFoj, where Fo and Fc are the observed and
calculated structure factor amplitudes, respectively.
d Rfree is equivalent to Rconv for a 5% subset of reflections not used in the
refinement.558 Chemistry & Biology 15, 552–562, June 2008 ª2008 Elsevier LtdProspects for Combination Therapy
Positive responses have been reported in imatinib-resistant
CML patients treated with the second-generation BCR-ABL in-
hibitors dasatinib and nilotinib (Kantarjian et al., 2006; Talpaz
et al., 2006). However, sequential treatment can result in the ex-
pansion of subclones with compound mutations rendering the
patient resistant to multiple inhibitors (Shah et al., 2007). This
finding argues that in order to minimize resistance, a cocktail
of agents that together inhibit a broad range of mutations will
be required, which is analogous to the use of cocktails to treat
HIV (Sawyers, 2005). What are the prospects for identifying sec-
ond-generation Aurora inhibitors suitable for simultaneous com-
binatorial treatments? We screened several Aurora inhibitors,
and all were resisted by the mutations described here, consis-
tent with the notion outlined above—that these mutations are
likely to affect a wide range of ATP-competitive inhibitors. There-
fore, rather than screening existing inhibitors for ones that block
the mutants described here, we suggest that these Aurora B var-
iants are considered as de novo drug targets. Identifying novel
chemical scaffolds that inhibit Aurora B Y156H and Aurora B
G160E/V may yield drugs suitable for combinations with existing
inhibitors.
Drug-Resistant Alleles as Target Validation Tools
A limitation when characterizing small molecules during the
drug-discovery process and as research tools is determining
whether the inhibitor-induced phenotypes are due to inhibition
of the desired target, as opposed to off-target effects. Conse-
quently, other approaches, such as RNA interference, chemical
genetics, and the expression of dominant negatives, are often
used to validate small-molecule phenotypes (Weiss et al.,
2007). However, such approaches can only ascertain whether
small-molecule-derived phenotypes are consistent with inhibi-
tion of the presumptive target; they do not demonstrate that
the effects are actually due to inhibition of the target. Here, by
expressing drug-resistant Aurora B alleles, we have unambigu-
ously demonstrated that the cytoxicity of ZM447439 is mediated
by inhibition of Aurora B. Furthermore, because the chromo-
some-alignment, spindle-checkpoint, and cell-division defects
induced by ZM447439 are all rescued by expression of the
same mutants, we have been able to demonstrate that these
phenotypes are also due to Aurora B inhibition.
VX-680 targets both Aurora A and Aurora B in cells (Harring-
ton et al., 2004; Tyler et al., 2007); however, we show that its
cytotoxicity is mediated largely via Aurora B. Similarly, because
the cell-division failure induced by 5 mM MLN8045 can be re-
verted by the drug-resistant mutants, this phenotype must
also be due to Aurora B inhibition. However, the mutants could
not restore cloning potential in 1–2 mM MLN8054, demonstrat-
ing that the cytotoxicity of this drug is not mediated via Aurora
B, but most likely represent Aurora A inhibition. The Y156H and
G160V/E mutations render Aurora B resistant to Hesperadin in
vitro, but they offer little protection against Hesperadin-in-
duced cell-division failure. Although many of the phenotypes
induced by Hesperadin appear to be due to Aurora B dysfunc-
tion (Hauf et al., 2003; Lipp et al., 2007), the cytokinesis failure
may therefore reflect inhibition of another target in addition to
Aurora B.All rights reserved
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Drug-Resistant Aurora B MutantsFigure 5. Structure of the Aurora B:INCENP-ZM447439 Complex
(A) Chemical structure of ZM447439.
(B) Aurora B60–361, from Xenopus laevis, consists of the N-terminal small lobe (dark gray), which contains the catalytically important aC helix (blue); a C-terminal
helical large lobe (light gray), which contains the activation loop (red); and a short C-terminal extension (green). In the structure, the activation loop is phosphor-
ylated on a conserved threonine residue as part of the activation mechanism and adopts an extended, active conformation; and a short C-terminal extension
(green). INCENP790–847 (orange) crowns the small lobe of Aurora B, stabilizing an active conformation of the kinase (Sessa et al., 2005). ZM447439, shown in
ball-and-stick representation and surrounded by a semitransparent-light blue surface, occupies the ATP-binding pocket at the interface between the small
and large lobes.
(C) Ball-and-stick representation of the interaction of ZM447439 with selected residues of Aurora B. Oxygen and nitrogen are shown in red and blue, respectively.
Carbon atoms in ZM447439 and Aurora B are white and yellow, respectively. A semitransparent molecular surface of ZM447439 is shown. Hydrogen bonds are
shown as dashed lines. An unbiased jFoj  jFcj electron density (red) map, contoured at 2.5 s, of ZM447439 is shown.
(D) A close-up of the interaction of ZM447439 with the hinge loop.
(E) Model of the G160V mutation (note that the equivalent residue in Xl Aurora B is named V176) showing a collision of the side chain with ZM447439.
(F) A structure of Aurora B:INCENP with bound AMP-PNP (F.S., F.V., and A.M., unpublished data) shows that the same substitution does not create a collision
with ATP.Together, these observations illustrate how drug-resistant mu-
tants provide powerful tools to delineate on- and off-target ef-
fects. In addition to teasing apart the effects of Aurora inhibitors
in cultured cells, generation of mice harboring the drug-resistant
Aurora B mutants should determine whether the antitumor ef-
fects and toxicity profiles of these drugs are mediated via inhibi-
tion of Aurora B or via an off-target effect.Chemistry & BiologySIGNIFICANCE
In the quest for novel anticancer drugs, considerable effort
continues to be focused on generating highly selective pro-
tein kinase inhibitors. The downside of selective inhibitors is
the emergence of subclones harboring mutations in the tar-
get kinase rendering themdrug resistant. To date,mutations15, 552–562, June 2008 ª2008 Elsevier Ltd All rights reserved 559
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Drug-Resistant Aurora B Mutantscausing resistance to tyrosine kinase inhibitors have arisen
in several targets, most notably in the receptor tyrosine
kinases BCR-ABL and EGFR. Here, we show that it is
mechanistically possible for resistance to emerge against
cytotoxic agents that target serine/threonine kinases re-
quired for cell-cycle control, specifically Aurora B. Indeed,
this is, to our knowledge, the first demonstration of drug
resistance arising in a cell-cycle kinase that is not an onco-
gene. One strategy aimed at limiting clinical resistance is to
use combinations of inhibitors that have distinct modes of
action, either in sequence or in parallel. However, the obser-
vation that the same mutations render Aurora B resistant to
three structurally diverse inhibitors indicates that these
agents share common modes of action, and, thus, they are
not suitable for combination therapies. Therefore, if the
Aurora kinases are tobeeffective oncology targets, the iden-
tification of novel chemical scaffolds that inhibit the
mutants described here will be essential for limiting the
emergence of clinical drug resistance. And, finally, the isola-
tion and use of drug-resistant mutants to delineate on- and
Figure 6. Aurora B Mutants Confer Resis-
tance to VX-680 and MLN8054
Transgenic DLD-1 lines were induced with tetra-
cycline, exposed to Aurora inhibitors, then ana-
lyzed.
(A) DNA-content histograms showing that Aurora
B Y156H reverts cell-division failure induced by
VX680.
(B) Colony formation assay showing that Aurora B
Y156H confers cell survival in 200 nM VX680.
(C) DNA-content histograms showing that Aurora
B G160V, Y156H, and H250Y confer limited resis-
tance to a Hesperadin.
(D) DNA-content histograms showing that Aurora
B Y156H reverts the cell-division failure induced
by 5 mM MLN8054, but not the cell-cycle delay
observed at 1 mM.
(E) Colony formation assay showing that Aurora B
Y156H is not cytoprotective at 1 mM MLN8054.
Flow cytometry analysis in (A), (C), and (D) was
performed after 24 hr drug exposures.
off-target effects demonstrates an im-
portant proof of principle that should
be applicable to other protein kinase
inhibitors.
EXPERIMENTAL PROCEDURES
Molecular Cell Biology and Small-Molecule
Inhibitors
HCT-116 and Flp-In TRex DLD-1 cells were as
described (Tighe et al., 2004; Girdler et al., 2006).
Total mRNA was isolated by using Trizol (Invitro-
gen), and Aurora cDNAs were amplified by using
Superscript One-Step RT-PCR (Invitrogen), then
sequenced. Site-directed mutagenesis was per-
formed by using QuickChange (Stratagene) with
pcDNA-FRT-TO Myc-Aurora B as templates
(Girdler et al., 2006). Stably transfected isogenic
DLD-1 cell lines were generated by using
Flp/FRT-mediated recombination; transgene ex-
pression was induced with 1 mg/ml tetracycline (Girdler et al., 2006). Taxol
was used at a final concentration of 10 mM. ZM447439, VX-680, Hesperadin,
and MLN8054 were as described (Ditchfield et al., 2003; Hauf et al., 2003;
Harrington et al., 2004; Manfredi et al., 2007). Colony formation assays, prolif-
eration assays, flow cytometry, immunofluorescence, immunoblotting, and
immunoprecipitation kinase assays were performed essentially as described
(Girdler et al., 2006).
Expression and Purification of Recombinant Proteins
For bacterial expression, cDNA segments encoding human Aurora B45–344 and
human INCENP835–903 were subcloned in a bicistronic pGEX-6P vector (Amer-
sham Biotech). Expression of Aurora B45–344:INCENP835–903 in Rosetta DE3 E.
coli cells at OD600 = 0.45–0.7 was induced for 12–16 hr at 18
C with 0.3 mM
IPTG. Bacterial pellets were resuspended in lysis buffer (50 mM Tris-HCl [pH
7.6], 400 mM NaCl, 1 mM DTT, 1 mM EDTA, 5% glycerol, Roche Complete
Protease Inhibitor Cocktail Tablets) and lysed by sonication, and the lysates
were clarified by centrifugation. The supernatants were incubated in lysis
buffer with 300 ml GST Sepharose Fast Flow (Amersham Biosciences) per liter
of bacterial culture for 4–5 hr at 4C. Beads were then washed with 30 volumes
of lysis buffer, equilibrated in cleavage buffer (50 mM Tris-HCl [pH 7.6], 300
mM NaCl, 1 mM DTT, 1 mM EDTA), then incubated with PreScission Protease
(Amersham Biosciences; 10 U/mg substrate) for 16 hr at 4C to liberate the
Aurora B:INCENP complex for subsequent analyses.560 Chemistry & Biology 15, 552–562, June 2008 ª2008 Elsevier Ltd All rights reserved
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Reactions were carried out in 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 150 mM
NaCl, 1 mM EDTA, 1 mM DTT. Aurora B45–344:INCENP835–903 at 50 nM was in-
cubated at 30C for 15 min in the presence of 200 mM ATP and 5.5 mM Histone
H3 (Roche). Reactions were initiated by the addition of ATP and MgCl2, termi-
nated by adding SDS-PAGE loading buffer, then separated by 15% SDS-
PAGE gel and transferred onto a nitrocellulose membrane. The membrane
was blocked in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% (v/v) Tween
(TBS-Tween), and 5% (w/v) milk for 1 hr, then incubated for 16 hr at 4C
with a monoclonal antibody against phospho-Ser10 Histone H3 (Upstate Bio-
technology, Inc.). Detection was performed by using an HRP-conjugated
secondary antibody and enhanced chemiluminescence at 30C (ECL, GE
Healthcare, Inc.).
Crystallization and Structure Determination
Expression, purification, and structure determination of Xl Aurora B60–361:IN-
CENP
790–847
have been described (Sessa et al., 2005). Crystals obtained by mi-
croseeding were gradually transferred in cryobuffer (19% PEG400, 100 mM
Bis-Tris-Propane [pH 6.5], 2 mM TCEP), then incubated with 1/100 (v/v) of
a 10 mM solution of ZM447439 dissolved in DMSO. After a 16 hr incubation
with the inhibitor, crystals were flash frozen. X-ray diffraction data from single
crystals were collected at beamline ID14-3 at the European Synchroton Radia-
tion Facility (Grenoble, France). Data processing was carried out by using
DENZO/SCALEPACK (Otwinowski and Minor, 1997). For subsequent calcula-
tions, we used the CCP4 suite (CCP4, 1994). Molecular replacement was car-
ried out with MOLREP (Vagin and Teplyakov, 1997) by using the Aurora B coor-
dinates as a search model (PDB code: 2BFX). Iterative model building was
carried out with Coot (Emsley and Cowtan, 2004) and Refmac (Murshudov
etal., 1997), resulting ina modelwithgood stereochemical parameters (Table1).
ACCESSION NUMBERS
Coordinates have been deposited in the Protein Data Bank with accession
code 2VRX.
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